Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction

BACKGROUND AND OBJECTIVES: Large clinical studies of sodium/glucose cotransporter 2 (SGLT2) inhibitors have shown a significant beneficial effect on heart failure-associated hospitalization and cardiovascular events. As SGLT2 is known to be absent in heart cells, improved cardiovascular outcomes are...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Soo Yong, Lee, Tae Wook, Park, Gyu Tae, Kim, Jae Ho, Lee, Hyun-Chae, Han, Jung-Hwa, Yoon, Aeseon, Yoon, Dahye, Kim, Shukmann, Jung, Soon Myung, Choi, Jin Hee, Chon, Min Ku, Lee, Sang Hyun, Hwang, Ki Won, Kim, Jeongsu, Park, Yong Hyun, Kim, June Hong, Chun, Kook Jin, Hur, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925966/
https://www.ncbi.nlm.nih.gov/pubmed/33655725
http://dx.doi.org/10.4070/kcj.2020.0303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925966/
https://www.ncbi.nlm.nih.gov/pubmed/33655725
http://dx.doi.org/10.4070/kcj.2020.0303

Ejemplares similares